Baxter International Inc vs 8x8 Inc — how do they compare? Baxter International Inc trades at $27.61 (market cap $14.36B), while 8x8 Inc trades at $2.16 (market cap $323.54M). The key difference: Baxter International Inc is far larger — about 44.4× 8x8 Inc's market cap, and Baxter International Inc pays a 0.14% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals.
| BAX | EGHT | |
|---|---|---|
Market Cap | $14.36B | $323.54M |
Sector | Health | Technology |
52-Week High | $28.35 | $2.76 |
52-Week Low | $15.80 | $1.59 |
Enterprise Value | $21.88B | $590.46M |
Dividend Yield | 0.14% | — |
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.55, up 2.0% today, showing strong momentum after recent earnings beats. The stock is approaching its 52-week high of $29.35, with technical indicators signaling bullish momentum. Fundamentally, the company reported Q2 2026 earnings of $0.56 per share, beating estimates, and raised full-year guidance, though profitability metrics remain negative with a -9.27% net income margin. Recent news highlights operational improvements and strong demand for IV solutions.
The outlook is cautiously optimistic as Baxter demonstrates turnaround progress with raised guidance and earnings beats. Investment opportunity lies in continued operational execution and margin recovery, but risks include persistent negative profitability, high debt levels, and competitive pressures in the medtech space. Wall Street sentiment is mixed with 42% buy ratings but a consensus price target below current levels.
EGHT trades at $2.30, up 1.1% today, with a bullish technical signal from moving averages. The company shows strong revenue growth, with five consecutive quarters of year-over-year increases, and has beaten EPS estimates in recent quarters. Recent news highlights the launch of a new partner program and expansion of AI capabilities across its platform. However, the stock carries a high P/E ratio of 74.67, and the company reported a net loss of $27.21 million for 2025.
The outlook is cautiously optimistic, with analyst consensus pointing to significant upside with a $3.13 price target. Key opportunities include sustained revenue growth and AI-driven product expansion, while risks involve high valuation, debt levels, and the challenge of achieving consistent profitability. Institutional sentiment is mixed but leans positive.
Trailing returns across standard periods
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →